Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Other

J&uuml;rgen Bernhagen

Herwig Brunner

Frank Vitzthum

Georg Geiger

Afroditi Kapurniotu

Hans Lindner

Stefan Kiesewetter

Gu Nter Tovar

Elkin Bentsian

G&uuml;nter Tovar

Gabriele Tolle

Claus Kuhn

Hannes Dobler

Bentsian Elkine

The present invention relates to a method and an apparatus for separating substances from or in biological materials.

Method and sample mount system for the in situ separation and enrichment of substances

The invention relates to a method and a device for the isolation and purification of nucleic acids. According to the invention, after decomposition of a sample the nucleic acids present in said sample are isolated and purified.

Electrical integrated nucleic acid isolation, purification and detection

The patent relates to a method for spectroscopic and spectrofluorimetric determination of the interaction between materials. The determination takes place using apparatus consisting of several basins.

Method for differential spectroscopic measurements

An apparatus for isolating cell material from a tissue system and/or a liquid includes (1) a vessel open at the top, into which the cell material to be isolated can be introduced in the tissue system and/or the liquid; and (2) a separating device having a stamp-shaped configuration and including a flat separating disk having a peripheral edge fitting with the inner walls of the vessel in a fluid-tight manner and presenting at least one passage opening which is covered by a filter membrane, and which device can be inserted from the top into the vessel. The isolating disk pressurises the cell material inclusive of the tissue system and/or the liquid and acts thereupon with shearing forces by rotation. The cells and/or cell systems pass through the pores of the filter membrane whereas the residual tissue material is retained.

Device and method for isolating cell material out of a tissue medium and/or a liquid

Certain peptide molecules can be used as the basic structures (template molecules) for inhibiting and analysing amyloid formation and cytotoxicity in amyloid illnesses. These peptides have an effect on the molecules which are responsible for the amyloid illnesses (for their part amyloid-forming peptides and proteins). The peptides are thus either inhibitors themselves or agonists of amyloid formation and cytotoxicity or can serve as a template for identifying and producing further inhibitors and agonists and can be used as molecular tools during analysis. The peptide molecules have generally 3-15 amino acids, and preferably a maximum of 10 amino acids, and at least an active peptide sequence GA, preferably GAI, and even more preferably one selected from the group consisting of GAIL, SEQ ID NO: 1; FGAIL, SEQ ID NO: 2; NFGAIL, SEQ ID NO: 3; NNFGAIL, SEQ ID NO: 4; SNNFGAIL, SEQ ID NO: 5; NFGAILSS, SEQ ID NO: 6; SNNFGAILSS, SEQ NO: 7; or the group consisting of GAII, SEQ ID NO: 8; KGAII, SEQ ID NO: 9; NKGAII, SEQ ID NO: 10; SNKGAII, SEQ ID NO: 11; GSNKGAII, SEQ ID NO: 12; NKGAIIGL, SEQ ID NO: 13; GSNKGAIIGL, SEQ ID NO: 14; or the group consisting of GAVV, SEQ ID NO: 15; AGAVV, SEQ ID NO: 16; VAAGAVV, SEQ ID NO: 17; HVAAGAVV, SEQ ID NO: 18; AAGAVVGG, SEQ ID NO: 19; HVAAGAVVGG, SEQ ID NO: 20; AAGAVV, SEQ ID NO: 21. The peptide sequence generally has at least one hydrogen molecule, and preferably every second hydrogen molecule, of an amide bond replaced by a methyl group.

Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies

Growing community of inventors

Tübingen, Germany

Jürgen Bernhagen

Growing community of inventors

Tübingen, Germany

J&uuml;rgen Bernhagen

Jürgen Bernhagen